An unblinded randomized trial testing whether adding the Vitadio self-management app to standard care improves HbA1c in type 2 diabetes. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.
A small single-centre randomised trial testing weight-lowering hypoglycaemic agents plus a high-protein diet and moderate exercise against standard care for diabetes remission in adults with obesity. PICO summary and expert commentary.
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
A 149-patient inpatient randomized trial found an AI insulin titration system noninferior to senior physicians for time-in-range glucose control. PICO summary and expert commentary.
An acute randomised trial in 57 sedentary adults with type 2 diabetes found a single HIIT session raised flow-mediated dilation more than moderate continuous exercise, while both lowered post-exercise glucose. PICO summary and expert commentary.
The PARTNER study is a published trial protocol, not a results paper: it describes the rationale and design of a randomised crossover trial of dapagliflozin plus continuous ketone monitoring in type 1 diabetes, with no outcomes yet reported. PICO summary and expert commentary.
A small 12-week factorial feeding trial in prediabetes found that shifting unsaturated fat intake to lunch rather than dinner improved insulin-sensitivity indices, while the primary postprandial glucose outcome was null. PICO summary and expert commentary.
A post-hoc sub-analysis of the open-label PROCEED RCT found ipragliflozin did not improve LV diastolic function overall, with only exploratory subgroup signals. PICO summary and expert commentary.